---
document_datetime: 2025-11-23 08:10:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ribavirin-teva.html
document_name: ribavirin-teva.html
version: success
processing_time: 0.1079371
conversion_datetime: 2025-12-27 18:05:59.073924
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ribavirin Teva

[RSS](/en/individual-human-medicine.xml/66479)

##### Withdrawn

This medicine's authorisation has been withdrawn

ribavirin

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Ribavirin Teva](#more-information-on-ribavirin-teva-1335)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 22 June 2021, the European Commission withdrew the marketing authorisation for Ribavirin Teva (ribavirin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Ribavirin Teva was granted marketing authorisation in the EU on 31 March 2009 for the treatment of chronic hepatitis C. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

Ribavirin Teva is a generic medicine of Rebetol.

The European Public Assessment Report (EPAR) for Ribavirin Teva is updated to indicate that the marketing authorisation is no longer valid.

Ribavirin Teva : EPAR - Summary for the public

English (EN) (617.01 KB - PDF)

**First published:** 16/11/2009

**Last updated:** 09/07/2021

[View](/en/documents/overview/ribavirin-teva-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-531)

български (BG) (850.92 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/bg/documents/overview/ribavirin-teva-epar-summary-public_bg.pdf)

español (ES) (680.49 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/es/documents/overview/ribavirin-teva-epar-summary-public_es.pdf)

čeština (CS) (823.41 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/cs/documents/overview/ribavirin-teva-epar-summary-public_cs.pdf)

dansk (DA) (678.19 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/da/documents/overview/ribavirin-teva-epar-summary-public_da.pdf)

Deutsch (DE) (679.34 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/de/documents/overview/ribavirin-teva-epar-summary-public_de.pdf)

eesti keel (ET) (678.07 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/et/documents/overview/ribavirin-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (844.54 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/el/documents/overview/ribavirin-teva-epar-summary-public_el.pdf)

français (FR) (679.2 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/fr/documents/overview/ribavirin-teva-epar-summary-public_fr.pdf)

italiano (IT) (678.54 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/it/documents/overview/ribavirin-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (845.84 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/lv/documents/overview/ribavirin-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (787.98 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/lt/documents/overview/ribavirin-teva-epar-summary-public_lt.pdf)

magyar (HU) (815.36 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/hu/documents/overview/ribavirin-teva-epar-summary-public_hu.pdf)

Malti (MT) (825.48 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/mt/documents/overview/ribavirin-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (678.53 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/nl/documents/overview/ribavirin-teva-epar-summary-public_nl.pdf)

polski (PL) (831.67 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/pl/documents/overview/ribavirin-teva-epar-summary-public_pl.pdf)

português (PT) (679.16 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/pt/documents/overview/ribavirin-teva-epar-summary-public_pt.pdf)

română (RO) (785.16 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/ro/documents/overview/ribavirin-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (819.95 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/sk/documents/overview/ribavirin-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (779.52 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/sl/documents/overview/ribavirin-teva-epar-summary-public_sl.pdf)

Suomi (FI) (678.26 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/fi/documents/overview/ribavirin-teva-epar-summary-public_fi.pdf)

svenska (SV) (677.35 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/sv/documents/overview/ribavirin-teva-epar-summary-public_sv.pdf)

## Product information

Ribavirin Teva : EPAR - Product Information

English (EN) (1.37 MB - PDF)

**First published:** 16/11/2009

**Last updated:** 09/07/2021

[View](/en/documents/product-information/ribavirin-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-158)

български (BG) (2.71 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/bg/documents/product-information/ribavirin-teva-epar-product-information_bg.pdf)

español (ES) (1.3 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/es/documents/product-information/ribavirin-teva-epar-product-information_es.pdf)

čeština (CS) (2.33 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/cs/documents/product-information/ribavirin-teva-epar-product-information_cs.pdf)

dansk (DA) (1.27 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/da/documents/product-information/ribavirin-teva-epar-product-information_da.pdf)

Deutsch (DE) (1.38 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/de/documents/product-information/ribavirin-teva-epar-product-information_de.pdf)

eesti keel (ET) (1.24 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/et/documents/product-information/ribavirin-teva-epar-product-information_et.pdf)

ελληνικά (EL) (2.73 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/el/documents/product-information/ribavirin-teva-epar-product-information_el.pdf)

français (FR) (1.31 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/fr/documents/product-information/ribavirin-teva-epar-product-information_fr.pdf)

hrvatski (HR) (1.43 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/hr/documents/product-information/ribavirin-teva-epar-product-information_hr.pdf)

íslenska (IS) (1.3 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/is/documents/product-information/ribavirin-teva-epar-product-information_is.pdf)

italiano (IT) (1.38 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/it/documents/product-information/ribavirin-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (2.22 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/lv/documents/product-information/ribavirin-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.4 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/lt/documents/product-information/ribavirin-teva-epar-product-information_lt.pdf)

magyar (HU) (2.45 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/hu/documents/product-information/ribavirin-teva-epar-product-information_hu.pdf)

Malti (MT) (2.23 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/mt/documents/product-information/ribavirin-teva-epar-product-information_mt.pdf)

Nederlands (NL) (1.35 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/nl/documents/product-information/ribavirin-teva-epar-product-information_nl.pdf)

norsk (NO) (1.23 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/no/documents/product-information/ribavirin-teva-epar-product-information_no.pdf)

polski (PL) (2.39 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/pl/documents/product-information/ribavirin-teva-epar-product-information_pl.pdf)

português (PT) (1.26 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/pt/documents/product-information/ribavirin-teva-epar-product-information_pt.pdf)

română (RO) (1.46 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/ro/documents/product-information/ribavirin-teva-epar-product-information_ro.pdf)

slovenčina (SK) (2.22 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/sk/documents/product-information/ribavirin-teva-epar-product-information_sk.pdf)

slovenščina (SL) (2.15 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/sl/documents/product-information/ribavirin-teva-epar-product-information_sl.pdf)

Suomi (FI) (1.35 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/fi/documents/product-information/ribavirin-teva-epar-product-information_fi.pdf)

svenska (SV) (1.22 MB - PDF)

**First published:**

16/11/2009

**Last updated:**

09/07/2021

[View](/sv/documents/product-information/ribavirin-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0023 22/06/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ribavirin Teva : EPAR - All Authorised presentations

English (EN) (581.57 KB - PDF)

**First published:** 09/04/2009

**Last updated:** 09/07/2021

[View](/en/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-736)

български (BG) (671.8 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/bg/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (582.1 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/es/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (625.87 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/cs/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (582.09 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/da/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (581.71 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/de/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (582.28 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/et/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (666.52 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/el/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (582.5 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/fr/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (621.82 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/hr/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (616.2 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/is/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (581.61 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/it/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (664.36 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/lv/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (648.21 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/lt/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (665.54 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/hu/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (664.26 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/mt/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (581.59 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/nl/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (616.73 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/no/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (663.9 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/pl/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (582.27 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/pt/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (645.37 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/ro/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (627.33 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/sk/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (597 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/sl/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (581.7 KB - PDF)

**First published:**

09/04/2009

**Last updated:**

09/07/2021

[View](/fi/documents/all-authorised-presentations/ribavirin-teva-epar-all-authorised-presentations_fi.pdf)

## Product details

Name of medicine Ribavirin Teva Active substance ribavirin International non-proprietary name (INN) or common name ribavirin Therapeutic area (MeSH) Hepatitis C, Chronic Anatomical therapeutic chemical (ATC) code J05AB04

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Ribavirin Teva is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used.

There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e. not alfa-2b).

**Naïve patients**

*Adult patients*

Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA.

*Paediatric patients (children 3 years of age and older and adolescents)*

Ribavirin Teva is indicated, in a combination regimen with interferon alfa2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.

When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis.

**Previous treatment failure patients**

*Adult patients*

Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.

## Authorisation details

EMA product number EMEA/H/C/001018

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Swensweg 5

Marketing authorisation issued 31/03/2009 Withdrawal of marketing authorisation 22/06/2021 Revision 15

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ribavirin Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (834.43 KB - PDF)

**First published:** 16/11/2009

**Last updated:** 09/07/2021

[View](/en/documents/procedural-steps-after/ribavirin-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Ribavirin Teva : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/318704/2014

English (EN) (638.83 KB - PDF)

**First published:** 11/06/2014

**Last updated:** 09/07/2021

[View](/en/documents/scientific-conclusion/ribavirin-teva-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Ribavirin Teva-H-C-1018-II-11 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/461705/2013

English (EN) (794.98 KB - PDF)

**First published:** 18/09/2013

**Last updated:** 09/07/2021

[View](/en/documents/variation-report/ribavirin-teva-h-c-1018-ii-11-epar-assessment-report-variation_en.pdf)

Ribavirin Teva-H-C-1018-A20-08 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/12875/2013

English (EN) (906.46 KB - PDF)

**First published:** 12/03/2013

**Last updated:** 09/07/2021

[View](/en/documents/variation-report/ribavirin-teva-h-c-1018-a20-08-epar-assessment-report-article-20_en.pdf)

## Initial marketing authorisation documents

Ribavirin Teva : EPAR - Public assessment report

English (EN) (915.88 KB - PDF)

**First published:** 17/04/2009

**Last updated:** 09/07/2021

[View](/en/documents/assessment-report/ribavirin-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ribavirin Teva

English (EN) (791.84 KB - PDF)

**First published:** 21/01/2009

**Last updated:** 09/07/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ribavirin-teva_en.pdf)

#### More information on Ribavirin Teva

Questions and answers on the review of medicines for which studies have been conducted at Texas-based Cetero Research facility

Reference Number: EMA/796016/2012 Rev 1

English (EN) (652.34 KB - PDF)

**First published:** 14/12/2012

**Last updated:** 09/07/2021

[View](/en/documents/referral/questions-and-answers-review-medicines-which-studies-have-been-conducted-texas-based-cetero-research-facility_en.pdf)

**This page was last updated on** 09/07/2021

## Share this page

[Back to top](#main-content)